Biotech Hangout cover image

Biotech Hangout

Episode 100

May 10, 2024
Special guest Adam Feuerstein joins hosts in discussing Q1 earning reports, ONO's acquisition of Deciphera, X4's FDA approval, COVID fatigue, Biden’s Cancer Moonshot, drugmaker lawsuits, FTC targeting 'junk' patents, and emerging safety concerns in MorphoSys' study. Other topics include BridgeBio spinning out an oncology company, US government reclassifying marijuana, and more industry insights.
01:00:03

Episode guests

Podcast summary created with Snipd AI

Quick takeaways

  • BridgeBio shifts focus to oncology with new subsidiary, emphasizing novel drug candidates like G12C KRAS inhibitor.
  • FTC challenges patents in Orange Book, aiming to reclassify marijuana for medical research advancements.

Deep dives

Bridge Bio Spin's Out Oncology Company

Bridge Bio announced a $200 million private financing and corporate divestiture of its oncology subsidiary, pivoting towards a new company called Bridge Bio Oncology Therapeutics. This move allows them to focus on new drug candidates like a G12C KRAS on inhibitor, a PI3K alpha, and a G12C multi-inhibitor to enter the oncology space.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode